Shots: The agreement involves Astellas to pay an upfront payment of £85Mn to Quethera’s shareholder’s Quethera uses recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal […]readmore
Tags : Gene Therapy program